New combo therapy aims to keep High-Risk nasopharyngeal cancer at bay
NCT ID NCT06093061
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a year-long combination of tislelizumab (an immunotherapy) and low-dose capecitabine (a chemotherapy pill) can prevent cancer relapse in 53 patients with high-risk nasopharyngeal carcinoma. Participants have already received standard chemotherapy and radiation, but still have detectable Epstein-Barr virus DNA in their blood, indicating a higher risk of the cancer returning. The main goal is to see how many patients remain cancer-free two years after starting treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab and capecitabine
What this could lead to
If successful, this combination could improve disease-free survival for high-risk nasopharyngeal carcinoma patients who have a higher chance of relapse.
What could go wrong
This is a small, early-phase trial with only 53 participants and no comparison group, so results may not apply broadly. Side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Centre Singapore
RECRUITINGSingapore, 168583, Singapore
-
Tan Tock Seng Hospital
RECRUITINGSingapore, 308433, Singapore